Zhitong Financial App News, Beida Pharmaceutical (300558.SZ) issued an announcement. Recently, the company learned that the marketing license application for ensartinib hydrochloride capsules (hereinafter referred to as “ensartinib”) declared by the company's holding subsidiary Xdiscovery Holdings, Inc. (hereinafter referred to as “Xdiscovery”) has obtained positive opinions from the European Medicines Agency (“EMA”) Human Drugs Commission (hereinafter referred to as “CHMP”). The CHMP recommended approval for the use of ensatinib as an “late anaplastic lymphoma kinase (ALK) positive late The period is not small “Treatment of Adult Patients with Cellular Lung Cancer (NSCLC)”. The European Commission (hereinafter referred to as “EC”) will make a final decision on the listing license application based on the positive opinion of the CHMP. There is still uncertainty about whether the listing license application will be approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.